Literature DB >> 1346965

The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior.

B D Kretschmer1, B Zadow, T L Volz, L Volz, W J Schmidt.   

Abstract

The effects of competitive (CGP 37849 and CGP 39551) and non-competitive (dizocilpine) N-methyl-D-aspartate (NMDA) antagonists were tested in three animal models (catalepsy, sniffing, locomotion) and, in addition, the modulation of these effects by an agonist of the strychnine-insensitive glycine binding site was investigated. Both competitive and non-competitive NMDA antagonists reduced neuroleptic-induced catalepsy. Weak sniffing was induced by the competitive antagonist but strong sniffing by the non-competitive NMDA antagonist. Due to muscle relaxation the competitive antagonist reduced locomotion, in contrast to stimulation of locomotor activity induced by the non-competitive NMDA antagonist. The glycine agonist (D-cycloserine) potentiated the effects of the non-competitive but antagonized those of the competitive NMDA antagonist.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1346965     DOI： 10.1007/bf01253108

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  47 in total

1.  NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus.

Authors:  A Imperato; M G Scrocco; S Bacchi; L Angelucci
Journal:  Eur J Pharmacol       Date:  1990-10-23       Impact factor: 4.432

2.  An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy.

Authors:  R B Rosse; B L Schwartz; M P Leighton; R E Davis; S I Deutsch
Journal:  Clin Neuropharmacol       Date:  1990-08       Impact factor: 1.592

Review 3.  A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine.

Authors:  S I Deutsch; J Mastropaolo; B L Schwartz; R B Rosse; J M Morihisa
Journal:  Clin Neuropharmacol       Date:  1989-02       Impact factor: 1.592

Review 4.  The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system.

Authors:  D T Monaghan; R J Bridges; C W Cotman
Journal:  Annu Rev Pharmacol Toxicol       Date:  1989       Impact factor: 13.820

5.  Allocentric spatial learning by hippocampectomised rats: a further test of the "spatial mapping" and "working memory" theories of hippocampal function.

Authors:  R G Morris; J J Hagan; J N Rawlins
Journal:  Q J Exp Psychol B       Date:  1986-11

6.  Effects of D-cycloserine and cycloleucine, ligands for the NMDA-associated strychnine-insensitive glycine site, on brain-stimulation reward and spontaneous locomotion.

Authors:  L J Herberg; I C Rose
Journal:  Pharmacol Biochem Behav       Date:  1990-08       Impact factor: 3.533

7.  D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes.

Authors:  G B Watson; M A Bolanowski; M P Baganoff; C L Deppeler; T H Lanthorn
Journal:  Brain Res       Date:  1990-02-26       Impact factor: 3.252

8.  The effect of MK-801 and other antagonists of NMDA-type glutamate receptors on brain-stimulation reward.

Authors:  L J Herberg; I C Rose
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

9.  Detection of the nueroleptic properties of clozapine, sulpiride and thioridazine.

Authors:  B Costall; R J Naylor
Journal:  Psychopharmacologia       Date:  1975-07-23

10.  A simple and rapid method for assessing similarities among directly observable behavioral effects of drugs: PCP-like effects of 2-amino-5-phosphonovalerate in rats.

Authors:  W Koek; J H Woods; P Ornstein
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530
View more
  11 in total

1.  The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy.

Authors:  B Zadow; W J Schmidt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-01       Impact factor: 3.000

2.  Synergistic interactions between NMDA-antagonists and L-dopa on activity in MPTP-treated mice.

Authors:  A Fredriksson; C Gentsch; T Archer
Journal:  J Neural Transm Gen Sect       Date:  1994

3.  The adenosine receptor antagonist theophylline induces a monoamine-dependent increase of the anticataleptic effects of NMDA receptor antagonists.

Authors:  W Hauber; M Münkle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-07       Impact factor: 3.000

4.  Neuroleptic-like effects of gamma-hydroxybutyrate: interactions with haloperidol and dizocilpine.

Authors:  Rajkumar J Sevak; Charles P France; Wouter Koek
Journal:  Eur J Pharmacol       Date:  2004-01-12       Impact factor: 4.432

Review 5.  Glutamate receptors as therapeutic targets for Parkinson's disease.

Authors:  Kari A Johnson; P Jeffrey Conn; Colleen M Niswender
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

Review 6.  Glutamate receptors and Parkinson's disease: opportunities for intervention.

Authors:  Michael J Marino; Ornella Valenti; P Jeffrey Conn
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

7.  Glycine site antagonists abolish dopamine D2 but not D1 receptor mediated catalepsy in rats.

Authors:  B D Kretschmer; B Winterscheid; W Danysz; W J Schmidt
Journal:  J Neural Transm Gen Sect       Date:  1994

8.  d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study.

Authors:  N G Cascella; F Macciardi; C Cavallini; E Smeraldi
Journal:  J Neural Transm Gen Sect       Date:  1994

9.  Effects of D-cycloserine and (+)-HA-966 on the locomotor stimulation induced by NMDA antagonists and clonidine in monoamine-depleted mice.

Authors:  M L Carlsson; G Engberg; A Carlsson
Journal:  J Neural Transm Gen Sect       Date:  1994

10.  Differential effects of D-cycloserine and amantadine on motor behavior and D2/3 receptor binding in the nigrostriatal and mesolimbic system of the adult rat.

Authors:  Susanne Nikolaus; Hans-Jörg Wittsack; Frithjof Wickrath; Anja Müller-Lutz; Hubertus Hautzel; Markus Beu; Christina Antke; Eduards Mamlins; Maria Angelica De Souza Silva; Joseph P Huston; Gerald Antoch; Hans-Wilhelm Müller
Journal:  Sci Rep       Date:  2019-11-06       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.